Brain zaps may boost memory in schizophrenia patients
NCT ID NCT01545999
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a brain stimulation technique called paired associative stimulation (PAS) using transcranial magnetic stimulation (TMS) in 72 adults with schizophrenia. The goal is to see if daily sessions over two weeks can improve working memory, as measured by a letter-matching task. Researchers will also use EEG to track brain activity changes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial Magnetic Stimulation (TMS)
- What this could lead to
- If successful, this could point toward a non-drug treatment to improve memory and thinking in people with schizophrenia.
- What could go wrong
- This is an early-stage study with only 72 participants, and it is not testing a cure. The effects may be small or not last long, and the treatment requires daily sessions for two weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 72 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2012
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for patients: * Age 18 or above * All races and ethnicities. * Females and males. * Meet DSM-IV TR criteria for a current diagnosis of schizophrenia or schizoaffective disorder. * Clinically stable as operationalized by (1) either having not been hospitalized within 3 months or having been hospitalized for 3 months or more prior to assessment, and (2) having had no change in antipsychotic medication dosage within the 4 weeks prior to assessment. * Willingness and ability to speak English * Willingness to provide informed consent * Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice. Exclusion Criteria for patients: * Meets criteria for a cognitive disorder secondary to a neurological or other medical disorder affecting the central nervous system (for example, multiple sclerosis, history of traumatic brain injury, stroke, untreated hypothyroidism). * Mini Mental Status Examination score of 17 and less because a subject with a very low MMSE score is unlikely to be able to compete the NP battery. * Diagnosis of bipolar disorder or current major depressive episode. * Meets diagnostic criteria for current alcohol or other drug dependence within 6 months of testing * Electroconvulsive Therapy (ECT) within 6 months of testing. * Left handedness. * Incompetency to consent Inclusion Criteria for controls: * Age 18 or above * Willingness and ability to speak English * Willingness to provide informed consent * Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice. Exclusion Criteria for controls: * DSM IV TR psychiatric diagnosis except for simple phobias or an adjustment disorder. * Other neurological disorder affecting central nervous system. * Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks. * Family history of a primary psychotic disorder in a first-degree relative. * Left handedness.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
Toronto, Ontario, M6J 1H4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia